RESMED INC (RMD)
US7611521078 - Common Stock
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy ...
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
The alliance with Health Gorilla will provide MatrixCare customers with more than 220 million patient records to streamline workflows and improve patient outcomes.
ResMed Announces Participation in the RBCCM Global Healthcare Conference
ResMed Now #262 Largest Company, Surpassing Discover Financial Services
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78
On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78.
What's going on in today's session: S&P500 movers
What's going on in today's session: S&P500 movers
What's going on in today's session: S&P500 gap up and gap down stocks
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
S&P 500 Movers: RMD, TSLA
Why ResMed Stock Is Soaring Today
Investors liked the healthcare technology company's latest quarterly update.
S&P 500 Movers: INTC, RMD
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates.
RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ResMed (NYSE:RMD) just reported results for the third quarter of 2024.ResMed re...
RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024
RMD stock results show that ResMed beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of...
Noteworthy Thursday Option Activity: RMD, MDXG, XOM
RMD June 21st Options Begin Trading
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
Wednesday Sector Laggards: Healthcare, Technology & Communications
Notable Wednesday Option Activity: RMD, HES, STLD
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea.
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the...